S-1: Actuate Therapeutics Files for $50 Million Common Stock Offering via B. Riley Purchase Agreement

Actuate Therapeutics intends to offer up to 3,904,374 shares of common stock through a committed equity facility with B. Riley Principal Capital II, potentially raising up to $50 million for working capital and general corporate purposes.

Summary

• Actuate Therapeutics has filed a registration statement for the offer and sale of up to 3,904,374 shares of its common stock.
• These shares may be issued to B. Riley Principal Capital II under a common stock purchase agreement, potentially providing Actuate with up to $50 million in gross proceeds.
• The company will not receive any proceeds from the resale of shares by B. Riley Principal Capital II.
• The timing and amount of any sales of common stock to B. Riley Principal Capital II are at Actuate's sole discretion.
• The per-share purchase price will be determined based on the volume-weighted average price (VWAP) of the common stock during a specified period, less a 3.0% discount.
• Actuate intends to use any proceeds received for working capital and general corporate purposes.
• The company has agreed to pay B. Riley Principal Capital II a cash commitment fee of up to $500,000.
• Actuate is an emerging growth company and a smaller reporting company, which allows it to comply with certain reduced public company reporting requirements.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the offering provides potential funding, it also carries risks of dilution and market volatility. The company's financial condition and dependence on a single product candidate temper any strong positive outlook.

Positives

• The committed equity facility provides Actuate Therapeutics with potential access to up to $50 million in funding.
• The company retains control over the timing and amount of any sales of common stock to B. Riley Principal Capital II.
• The proceeds from any sales will be used for working capital and general corporate purposes, providing financial flexibility.
• The company's existing listing on the Nasdaq Global Market provides liquidity for the common stock.

Negatives

• The company will not receive any proceeds from the resale of shares by B. Riley Principal Capital II.
• The company is responsible for expenses related to the registration of the shares.
• The company is subject to limitations on issuing shares to B. Riley Principal Capital II under Nasdaq rules.
• The company's existing stockholders will experience dilution due to the issuance of new shares.

Risks

• The actual number of shares sold and the gross proceeds received are uncertain and depend on market conditions.
• Investors who buy shares at different times may pay different prices.
• Sales of a substantial number of securities could cause the price of the common stock to fall.
• The management team has broad discretion over the use of the net proceeds.
• The company has a limited operating history and has incurred significant operating losses.
• The company's financial condition raises substantial doubt as to its ability to continue as a going concern.
• The company will require substantial additional capital in the near term to finance its operations.
• The company is dependent on the success of elraglusib, its only product candidate.

Future Outlook

The company expects that any proceeds received from such sales of Common Stock to B. Riley Principal Capital II will be used for working capital and general corporate purposes.

Industry Context

This offering is a common financing strategy for clinical-stage biopharmaceutical companies to raise capital to fund ongoing research and development activities. The use of a committed equity facility provides flexibility in accessing capital based on market conditions and the company's needs.

Comparison to Industry Standards

• Comparable companies such as XOMA Corporation and Mustang Bio have also utilized committed equity facilities to raise capital.
• The 3.0% discount to VWAP is within the typical range for these types of agreements.
• The $50 million commitment is a moderate amount compared to other deals in the biotech sector, reflecting the company's current stage of development.

Related Party Transactions

• The offering involves a transaction with B. Riley Principal Capital II, LLC, a related party due to its affiliation with B. Riley Securities, Inc.

Stakeholder Impact

• Existing shareholders will experience dilution of their ownership stake.
• The company's employees and other stakeholders may benefit from the increased financial stability provided by the offering.
• The company's customers and suppliers may see a positive impact from the company's ability to continue its operations and development programs.

Next Steps

• The registration statement must be declared effective by the SEC.
• The company may then elect to sell shares of common stock to B. Riley Principal Capital II at its discretion.
• The company may need to file additional registration statements to register additional shares if it elects to sell more than 3,904,374 shares.

Key Dates

Keywords

common stock, B. Riley Principal Capital II, committed equity facility, elraglusib, offering, Actuate Therapeutics, registration statement, shares, purchase agreement, securities